Diabetes is a “game-changing” drug that can help lower obesity by one-fifth of body weight, according to a study.
Participants who were given a weekly dose of tirzepatid along with their diet and exercise regimen lost an average of 3.10 lbs in a 72-week trial.
Scientists have divided 2,500 overweight and obese people into obesity groups into four groups. They were given three doses of placebo or a placebo.
In the highest dose group (15 mg) more than half of the people lost 20 percent of their body weight.
Tirzepatid works by mimicking body hormones that help people feel full after a meal.
These tend to be low in obese people and may be due to their efforts to maintain weight even after exercise.
A drug that “changes the game” of diabetes can help get rid of obesity by 20 percent of body weight, a trial suggests (stock image)
Volunteers who took the most tirzepatid, 15 mg, lost an average of 3. 10 lbs.
HOW SHOULD A BALANCED DIET BE?
Meals should be based on potatoes, bread, rice, pasta or starchy carbohydrates, ideally wholegrain, according to the NHS.
• Eat at least 5 servings of fruits and vegetables every day. Fresh, frozen, dried and canned fruits and vegetables are counted
• Base meals on potatoes, bread, rice, pasta or starch carbohydrates, ideally wholegrain.
• 30 grams of fiber per day: all this is the same as eating: 5 pieces of fruit and vegetables, 2 whole wheat cereal biscuits, 2 thick slices of bread and a large baked potato peel.
• Have some dairy or dairy alternatives (such as soy drinks) by choosing lower fat and sugar options.
• Eat beans, legumes, fish, eggs, meat and other protein (including 2 parts of fish per week, one of which should be oily)
• Choose unsaturated and spread oils and consume them in small quantities
• Drink 6-8 glasses / glass of water a day
• Adults should have less than 6 g of salt and 20 g of saturated fat per day for women or 30 g for men.
Source: NHS Eatwell Guide
But it is well known that the drug causes side effects such as vomiting and diarrhea, and experts warn that weight loss can help people regain weight.
Dr. Ania Jastreboff of Yale University, the lead author of the study, told The Guardian that obesity should be treated like any other serious health condition.
“We should treat obesity in the same way that we treat any chronic disease – with effective and safe approaches to the underlying disease mechanisms – and these results underscore the fact that tirzepatid is doing so,” he said.
But Professor Tom Sanders, an expert in nutrition and dietetics at King’s College London, said the drug also had concerns about the effect on the pancreas.
He added: “This class of drugs only works when participants adhere to the low-calorie diet prescribed with the drug, so it’s not a magic bullet.”
Tirzepatide Lilly is a US pharmaceutical company that costs $ 974 (£ 775) for a four-week course.
One-third of patients reported side effects from taking tirzepatid, which may include nausea, diarrhea, constipation, and vomiting.
Participants in the test were from the USA, Argentina, Brazil, China, India, Japan, Mexico, Russia and Taiwan.
The results were published in the New England Journal of Medicine.
Tirzepatide combines glucagon-like peptide-1 (GLP-1) receptor agonists and another similar drug known as glucose-dependent insulinotropic peptide or GIP.
GLP-1 receptor agonists have been in use for about a decade and have transformed the treatment of type 2 diabetes.
Along with other diabetes medications, metformin, for example, works by mimicking hormones involved in digestion and helps patients who cannot lose weight through diet and exercise alone.
Drugs send signals to the brain, help reduce appetite, stimulate the body to use glucose in the blood, and reduce the amount of sugar that is digested and absorbed from food.
Many GLP-1 receptor agonists are currently available, including exenatide, liraglutide, and semaglutide, which are available as injections and pills.
However, some experts say that the introduction of a second active ingredient, GIP, makes tirzepatid more effective.
GIP works similar to GLP-1 receptor agonists, mimicking a natural digestive hormone that helps release insulin and absorb blood sugar.
Other studies have shown that once a week, tirzepatid has also been shown to be more effective in treating type 2 diabetes.
There are currently two weight loss drugs available in the NHS, orlistat and liraglutide.
More than 42 million adults in the UK will be overweight or obese by 2040, according to Cancer Research UK forecasts.
Orlistat prevents fat from being absorbed during digestion, and liraglutide deceives people into feeling full.
Both medications are usually prescribed only if a person has made a “significant” effort to lose weight through diet and exercise.
Obesity is one of the biggest health problems in the UK as recent data show 64% of adults were overweight or obese in 2019.
However, a study published by Cancer Research UK last month predicted that more than 42 million adults in the UK will be overweight by roughly 2040. 71 percent of the country.
This includes 36 percent of those who may be obese, which means they will be more likely to be in the lower severity category for the first time.
73.6 percent of adults in the U.S. are overweight or obese.
Being overweight or obese increases your risk of at least 13 different types of cancer and can lead to other dangerous health conditions, such as high blood pressure and type 2 diabetes.
Treating obesity-related diseases will cost the NHS £ 6 billion a year.
He said the drug, which “reduces weight by 20%”, is a game changer in the fight against obesity
Source link He said the drug, which “reduces weight by 20%”, is a game changer in the fight against obesity